[F31] Utilization, Outcomes, and Costs Related to the Use of Immune Checkpoint Inhibitors for the Treatment of Advanced Non-Small Cell Lung Cancer Among Individuals With Preexisting Autoimmune Diseases
Ente: National Cancer Institute
Scadenza: 2028-07-15
Importo max: $50,114
Paese: US
Descrizione
PROJECT SUMMARY/ABSTRACT
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for many patients with advanced
lung cancer. However, individuals with preexisting autoimmune diseases (ADs) have largely been excluded
from clinical trials due to concerns about immune-related adverse
Settori: National Cancer Institute
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.